IGF2BP1 is linked to immune checkpoint expression and tumor mutational burden (TMB), potentially affecting programmed cell death mechanisms through immune pathways and altering cancer cell survival and death rates.264. This evidence concerns the gene IGF2BP1 and neoplasm.